On the use of compressed sensing techniques for improving multistatic millimeter-wave portal-based personnel screening

This work develops compressed sensing techniques to improve the performance of an active three dimensional (3D) millimeter wave imaging system for personnel security screening. The system is able to produce a high-resolution 3D reconstruction of the whole human body surface and reveal concealed objects under clothing. Innovative multistatic millimeter wave radar designs and algorithms, which have been previously validated, are combined to improve the reconstruction results over previous approaches. Compressed Sensing techniques are used to drastically reduce the number of sensors, thus simplifying the system design and fabrication. Representative simulation results showing good performance of the proposed system are provided and supported by several sample measurement

The function of the university. From policy strategy to strategic policy

En este artículo examinamos la compleja relación entre política y universidad, dos conceptos con significado propio y que sólo en parte se fusionan respecto de la función de la universidad, que es el objeto principal de este estudio. Una vez delimitado el sentido de la contribución abordamos el marco de la coordinación competencial en nuestro país, junto con las directrices de la educación superior en el marco europeo y el énfasis actual en la búsqueda de la calidad universitaria como vía de desarrollo estratégico. Es justamente la cultura de la evaluación en la educación superior la que favorece un renovado análisis de la calidad en el contexto de una universidad de masas. Acorde con el notable reto derivado del Tratado de Maastricht, nos ocupamos del desarrollo de sistemas universitarios regionales y las políticas estratégicas asociadas a la definición de perfiles en las universidades. Finalmente, referimos algunos elementos importantes para una articulación de funciones que la universidad tendrá que plantearse en el nuevo sigloThe main objective of this article is to examine the complex relationship between policies and the university, two concepts, each with their own meanings that fuse only in part, with respect to the function of the universities themselves. Once the sense of this article has been established, we will analyse the framework given to the co-ordination of what should be done, why and by whom at the different Spanish universities. We will also analyse the guidelines for higher education within the European framework and the current emphasis given to the search for quality in universities, as a means to achieving a strategic development. It is precisely the «culture» of evaluation in higher education that helps towards a renewed analysis of this quality within the context of mass universities. In correlation with the important challenge derived from the Maastricht Treaty, we will deal with the development of regional university systems, as well as the strategic policies related to the definition of university profiles. Finally, we make reference to some important elements for the articulation of functions which universities will have to face in the next millenniumS

Momento Económico (46)

En este número Momento político: La ofensiva conservadora y la nueva Ley Federal del trabajo, Víctor M. Bemal Sahagún 2. ¿De cuál desarrollo y de cuáles regiones se trata en el Plan Nacional?, Angel Bassols Batalla 3. El Plan Nacional de Desarrollo 1989-1 994, Luis Fuentes Aguilar 10. Fernando Carmona de la Peña: Maestro emérito, Benito Rey Romay 12. José Luis Ceceiía Camez, Maestro emérito, Alma Chapoy Bonifaz y Salvador Martínez Della Roca 13. La deuda externa del llamado Tercer Mundo y la paz, Ramón Matínez Escamilla 14. Cananea: entre la quiebra y la privatización otro golpe a los trabajadores, José Casca Zamora 17. Paraestatales: Telmex y Pemex, Arturo Bonilla y Sergio Suárez Guevara 20. Los verdaderos alcances de la renegociación de la deuda externa de México, José Lorenzo Santos Valle 22. Indicadores económicos: México balance económico de los sectores primer semestre de 1989, Clara Eugenia Aranda 25. Temas de hoy José Antonio Moreno 32

Estimating the Prevalence of Cardiac Amyloidosis in Old Patients with Heart Failure—Barriers and Opportunities for Improvement: The PREVAMIC Study

Background: Cardiac amyloidosis (CA) could be a common cause of heart failure (HF). The objective of the study was to estimate the prevalence of CA in patients with HF. Methods: Observational, prospective, and multicenter study involving 30 Spanish hospitals. A total of 453 patients >= 65 years with HF and an interventricular septum or posterior wall thickness > 12 mm were included. All patients underwent a Tc-99m-DPD/PYP/HMDP scintigraphy and monoclonal bands were studied, following the current criteria for non-invasive diagnosis. In inconclusive cases, biopsies were performed. Results: The vast majority of CA were diagnosed non-invasively. The prevalence was 20.1%. Most of the CA were transthyretin (ATTR-CM, 84.6%), with a minority of cardiac light-chain amyloidosis (AL-CM, 2.2%). The remaining (13.2%) was untyped. The prevalence was significantly higher in men (60.1% vs 39.9%, p = 0.019). Of the patients with CA, 26.5% had a left ventricular ejection fraction less than 50%. Conclusions: CA was the cause of HF in one out of five patients and should be screened in the elderly with HF and myocardial thickening, regardless of sex and LVEF. Few transthyretin-gene-sequencing studies were performed in older patients. In many patients, it was not possible to determine the amyloid subtype

Relación entre calidad de vida, adherencia al tratamiento y nivel de conocimiento del paciente en hemodiálisis

Objetivo: Analizar la calidad de vida relacionada con la salud de los pacientes en tratamiento con hemodiálisis y su relación con su adherencia al tratamiento, comorbilidad y aspectos prácticos de autocuidado. Material y Método: Se ha llevado a cabo un estudio descriptivo, transversal, realizado en el Complexo Hospitalario de Ourense (España). Se incluyeron 51 pacientes en programa de hemodiálisis, con una edad media 64,96±13,03 años, y un tiempo en diálisis fue de 4,32±5,32 años. El 62,75% fueron hombres. Se analizó calidad de vida relacionada con la salud, comorbilidad, adherencia al tratamiento, nivel de conocimientos prácticos, además de variables sociodemográficas. Como instrumentos de medida: Índice comorbilidad de Charlson modificado, Test de Hermes, Kidney Disease Quality of Life-Short Form (KDQOL-SFTM). Se evaluaron conocimientos de autocuidado sobre cuidados generales, acceso vascular y dietéticos. Resultados: El índice de Comorbilidad medio fue de 4,42±2,83 puntos, y la adherencia al tratamiento, mediante el Test de Hermes de 2,78±0,84 puntos. En el análisis de regresión lineal, según modelo del componente físico, los valores del coeficiente Beta (β) asociado al sexo fueron β=0,304 (p=0,031) y a la comorbilidad de β=-0,436 (p=0,003). En el componente mental, coeficiente Beta (β) asociado al sexo β=0,330 (p=0,035) y la adherencia al tratamiento de β=0,311 (p=0,048) respectivamente. Conclusiones: El bajo nivel de conocimientos no se asocia a menor calidad de vida en la muestra estudiada. Los pacientes cumplidores obtienen mejores resultados en el componente mental estandarizado. A mayor comorbilidad menor calidad de vida

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.[Simple Summary] Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low–intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML.[Abstract] We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10−7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low–intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.This study was supported by the Centro de Investigación Biomédica en Red—Área de Oncología–del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369) and the Subdirección General de Investigación Sanitaria (Instituto de Salud Carlos III, Spain) grants PI16/01530, PI16/01661, PI19/01518, and PI19/00730, the CRIS against Cancer foundation, grant 2018/001, and by the Instituto de Investigación Hospital 12 de Octubre (IMAS12) (co-financed by FEDER funds). The study was supported internationally by Cancer Research UK, FCAECC and AIRC under the Accelerator Award Program

Biculturalism Dynamics: A Daily Diary Study of Bicultural Identity and Psychosocial Functioning

We examined two conceptualizations of bicultural identity – the Bicultural Identity Integration (BII) framework (cultural identity blendedness-distance and harmony-conflict) and cultural hybridizing and alternating (mixing one’s two cultural identities and/or switching between them). Utilizing data from a 12-day diary study with 873 Hispanic college students, we examined three research questions: (1) cross-sectional and longitudinal intercorrelations among these biculturalism components, (2) links among daily variability in these biculturalism components, and (3) how this daily variability predicts well-being and mental health outcomes over time. Bicultural hybridizing was positively related to, and longitudinally predicted by, both BII blendedness and harmony. Daily fluctuation scores for BII blendedness, BII harmony, and bicultural hybridizing were strongly interrelated. Well-being was negatively predicted by fluctuations in hybridizing, whereas internalizing symptoms were positively predicted by fluctuations in blendedness. These results are discussed in terms of what biculturalism is and how best to promote it

Puesta en marcha y coordinación del Máster en Optometría Avanzada y Salud Visual

Durante el curso 2015-2016 se va a implantar, en la Universidad de Alicante, el máster en Optometría Avanzada y Salud Visual, que fue aprobado por la ANECA en diciembre del 2014. Con el fin de coordinar las actividades docentes de cada una de las asignaturas del máster y dentro del Proyecto de Redes de Investigación en Docencia Universitaria 2014-2015, se ha creado una red formada por todos los profesores coordinadores de las asignaturas que constituyen el plan de estudios y que han participado en la realización de la memoria de dicho máster. En esta red se pretende la coordinación entre todas las asignaturas para organizar y desarrollar sus actividades con el fin de conseguir una buena distribución de la carga docente y un mejor aprovechamiento por parte del alumno de la docencia recibida. Por otra parte, dado que en este máster participan varias empresas del sector óptico y clínicas oftalmológicas es necesario determinar qué actividades propuestas por las empresas y clínicas se van a incluir en cada asignatura y planificarlas adecuadamente

Trabajo de coordinación para la implantación del Máster en Optometría Avanzada y Salud Visual

Durante el curso 2013-2014 la Universidad de Alicante ha propuesto la implantación del Master en Optometría Avanzada y Salud Visual, dicha solicitud está siendo actualmente evaluada por la ANECA. Con el fin de coordinar la docencia de este Máster y dentro del Proyecto de Redes de Investigación en Docencia Universitaria 2013-2014, se ha creado una red formada por todos los profesores que han participado en la elaboración del plan de estudios. En esta red esta red se pretende la coordinación entre las distintas asignaturas para elaborar las guías docentes a partir de los datos de las fichas enviadas a la ANECA. Por otra parte también se ha modificado la memoria atendiendo a las alegaciones realizadas por la ANECA. Y se han desarrollado los contenidos, la metodología de las distintas actividades propuestas con el fin de asegurar la consecución de las competencias previstas

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

PETHEMA Group.[Background] Options to treat elderly patients (≥65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy, hypomethylating agents with or without venetoclax, and supportive care. This multicenter, randomized, open-label, phase 3 trial was designed to assess the efficacy and safety of a fludarabine, cytarabine, and filgrastim (FLUGA) regimen in comparison with azacitidine (AZA).[Methods] Patients (n = 283) were randomized 1:1 to FLUGA (n = 141) or AZA (n = 142). Response was evaluated after cycles 1, 3, 6, and 9. Measurable residual disease (MRD) was assessed after cycle 9. When MRD was ≥0.01%, patients continued with the treatment until relapse or progressive disease. Patients with MRD < 0.01% suspended treatment to enter the follow-up phase. [Results] The complete remission (CR) rate after 3 cycles was significantly better in the FLUGA arm (18% vs 9%; P = .04), but the CR/CR with incomplete recovery rate at 9 months was similar (33% vs 29%; P = .41). There were no significant differences between arms in early mortality at 30 or 60 days. Hematologic toxicities were more frequent with FLUGA, especially during induction. The 1-year overall survival (OS) rate and the median OS were superior with AZA versus FLUGA: 47% versus 27% and 9.8 months (95% confidence interval [CI], 5.6-14 months) versus 4.1 months (95% CI, 2.7-5.5 months; P = .005), respectively. The median event-free survival was 4.9 months (95% CI, 2.8-7 months) with AZA and 3 months (95% CI, 2.5-3.5 months) with FLUGA (P = .001). [Conclusions] FLUGA achieved more remissions after 3 cycles, but the 1-year OS rate was superior with AZA. However, long-term outcomes were disappointing in both arms (3-year OS rate, 10% vs 5%). This study supports the use of an AZA backbone for future combinations in elderly patients with AML.This study was supported by the Spanish Biomedical Research Centre in Cancer of the Carlos III Health Institute (CB16/12/00369) and by the Carlos III Health Institute/Subdirectorate General for Health Research (FIS No. PI16/01661). Celgene provided the azacitidine and financial support for this study